-- （更新：目標價維持不變） 根據FactSet調查的分析師數據，Apellis Pharmaceuticals (APLS) 的平均評級為“持有”，平均目標價為40.82美元。 （報道北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究。研究機構可透過以下連結聯絡我們：https://www..com/contact-us）
Price: $40.95, Change: $-0.05, Percent Change: -0.11%
Related Articles
Australia
General Motors Could Top 2026 Outlook if Economy Stabilizes, UBS Says
General Motors (GM) could beat its 2026 outlook if the economy steadies, with further earnings growth likely into 2027 from cost control, electric vehicle profitability, stronger vehicle mix, and share buybacks, UBS said in a note emailed Wednesday.Investor concerns over commodity costs and demand risk misses General Motors' stronger execution, flexibility and spending control, according to the note.General Motors' outlook has some elements of conservatism because the company has not included a possible restocking of high-profit pickups and SUVs in its guidance, UBS said.The firm noted that possible USMCA trade talks are more likely to help the company than hurt it, though not included in its outlook.UBS kept its buy rating on General Motors and lowered its price target to $102 from $105.Price: $76.08, Change: $-2.87, Percent Change: -3.63%
$GM
Research
CGI Keeps Outperform Rating, C$150 Target at National Bank, Citing "Compelling Value", In-Line Q2 Results and "Light(er) Booking"
Price: $90.23, Change: $-10.41, Percent Change: -10.34%
$GIB-A.TO
Oil & Energy